Table 1 Characteristics and outcomes of 329 neutropenic episodes in 220 patients who received or not ciprofloxacin prophylaxis during neutropenia
Variable | Ciprofloxacin group N=219 | Control group N=110 | p value |
|---|---|---|---|
Underlying disease | |||
Acute myeloid leukemia | 48 (22) | 22 (20) | 0.69 |
Acute lymphoid leukemia | 48 (22) | 24 (22) | 0.98 |
Multiple myeloma | 56 (26) | 31 (28) | 0.61 |
Non-Hodgkin lymphoma | 40 (18) | 8 (7) | 0.008 |
Hodgkin lymphoma | 18 (8) | 15 (14) | 0.12 |
Other* | 9 (4) | 10 (9) | - |
Autologous HCT | 89 (41) | 53 (48) | 0.19 |
Allogeneic HCT | 30 (14) | 14 (13) | 0.81 |
Central venous catheter | 140 (64) | 73 (66) | 0.66 |
Performance status <50% | 25 (11) | 19 (17) | 0.14 |
Mucositis, any grade | 114 (52) | 76 (70) | <0.001 |
Grade 3 or 4 | 28 (13) | 16 (15) | 0.66 |
Duration (days) of neutropenia, mean ±SD (range) | 9 ± 6.3 (2–47) | 11 ± 7.9 (2–61) | 0.02 |
Duration (days) of severe neutropenia, mean ±SD (range) | 7 ± 5.2 (1–38) | 8 ± 6.9 (0–40) | 0.39 |
Fever | 159 (73) | 102 (93) | <0.001 |
Fever of unknown origin | 86 (39) | 52 (47) | 0.16 |
Bacteremia | 49 (22) | 36 (33) | 0.04 |
due to a single Gram-negative | 19 (9) | 13 (12) | 0.36 |
due to a single Gram-positive | 22 (10) | 18 (16) | 0.10 |
Polymicrobial | 8 (4) | 5 (4.5) | 0.77 |
Microbiologically documented without bacteremia | 3 (1) | 1 (1) | 1.00 |
Clinically documented | 21 (10) | 12 (11) | 0.71 |
Duration of hospitalization (days), mean ±SD (range) | 22 ± 13.9 (4 – 97) | 24 ± 10.4 (5 – 57) | 0.002 |
Duration of antimicrobial treatment (days) , mean ±SD (range) | 8 ± 7.6 (0 – 40) | 11 ± 7.0 (0 – 33) | <0.001 |
Receipt of carbapenem** | 79 (36) | 15 (14) | <0.001 |
Receipt of glycopeptide | 26 (24) | 14 (13) | 0.82 |
Death | 20 (9) | 12 (11) | 0.61 |